Cabozantinib Granted Breakthrough Therapy Designation for Kidney Cancer
the ONA take:
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to cabozantinib for treatment of advanced renal cell carcinoma (RCC) after a prior therapy administration.
The FDA designation was based on resulting data from METEOR, a phase 3 trial that compared cabozantinib vs everolimus in patients with advanced renal cell carcinoma. Participants all experienced disease progression after treatment with a VEGF receptor tyrosine kinase inhibitor.
Cabozantinib displayed a significant increase in progression-free survival when compared to everolimus treatment in the first 375 randomly chosen participants, with disease progression or death dropping by approximately 42 percent. RCC treatment has historically been limited to cytokine therapy before the more recent use of targeted therapies.
The Breakthrough Therapy Designation is assigned in cases where a drug demonstrates significant benefit and/or life-saving benefits when compared to traditional therapies.
The benefits of the Breakthrough Therapy Designation may include expedited review of a New Drug Application and the involvement of senior FDA managers in the review process.
Cabozantinib, marketed in capsule form under the trade name Cometriq, is currently FDA-approved for the treatment of metastatic medullary thyroid cancer. Cabozantinib inhibits the activity of tyrosine kinases active in oncogenesis, metastasis, and tumor angiogenesis processes.
The FDA has granted Breakthrough Therapy Designation to cabozantinib for treatment of advanced renal cell carcinoma.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|